STOCK TITAN

Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company, has announced the release date for its second quarter 2024 financial results. The company will disclose its earnings on Thursday, August 8, 2024, after the market closes. Following the release, Co-Diagnostics will host a conference call and webcast at 4:30 p.m. ET to discuss the results with analysts and institutional investors.

The call will feature key management figures, including CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. Interested parties can access the webcast through the company's investor relations website or join the conference call using the provided domestic and international phone numbers. For those unable to attend live, a recording will be made available on the company's website later.

Co-Diagnostics, Inc. (NASDAQ: CODX), una società di diagnostica molecolare, ha annunciato la data di rilascio per i suoi risultati finanziari del secondo trimestre 2024. L'azienda svelerà i suoi guadagni giovedì 8 agosto 2024, dopo la chiusura del mercato. Dopo il rilascio, Co-Diagnostics ospiterà una conference call e webcast alle 16:30 ET per discutere i risultati con analisti e investitori istituzionali.

La chiamata presenterà figure chiave della gestione, tra cui il CEO Dwight Egan, il CFO Brian Brown e il Responsabile delle Relazioni con gli Investitori Andrew Benson. Le parti interessate possono accedere al webcast attraverso il sito web delle relazioni con gli investitori dell'azienda o partecipare alla conference call utilizzando i numeri di telefono nazionali e internazionali forniti. Per coloro che non possono partecipare dal vivo, una registrazione sarà disponibile sul sito web dell'azienda in seguito.

Co-Diagnostics, Inc. (NASDAQ: CODX), una empresa de diagnóstico molecular, ha anunciado la fecha de lanzamiento de sus resultados financieros del segundo trimestre de 2024. La compañía divulgará sus ganancias el jueves 8 de agosto de 2024, después de que cierre el mercado. Tras el lanzamiento, Co-Diagnostics llevará a cabo una llamada de conferencia y webcast a las 4:30 p.m. ET para discutir los resultados con analistas e inversores institucionales.

La llamada contará con la participación de figuras clave de la dirección, incluyendo al CEO Dwight Egan, al CFO Brian Brown, y al Jefe de Relaciones con Inversores Andrew Benson. Las partes interesadas pueden acceder al webcast a través del sitio web de relaciones con inversores de la compañía o unirse a la llamada de conferencia utilizando los números de teléfono nacional e internacional proporcionados. Para aquellos que no puedan asistir en vivo, se disponibilizará una grabación en el sitio web de la compañía más tarde.

코다이아그노스틱스(CODX) Inc. (NASDAQ: CODX)는 분자 진단 회사로, 2024년 2분기 재무 결과 발표 날짜를 발표했습니다. 이 회사는 2024년 8월 8일 목요일 시장 마감 후 수익을 공개할 예정입니다. 발표 이후 코다이아그노스틱스는 오후 4시 30분(ET)에 애널리스트와 기관 투자자들과 결과를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 개최할 것입니다.

이번 콜에는 CEO Dwight Egan, CFO Brian Brown, 그리고 투자자 관계 책임자 Andrew Benson와 같은 주요 경영진들이 참석할 예정입니다. 관심 있는 분들은 회사의 투자자 관계 웹사이트를 통해 웹캐스트에 접속하거나 제공된 국내 및 국제 전화 번호를 사용하여 컨퍼런스 콜에 참여할 수 있습니다. 실시간으로 참석할 수 없는 분들을 위해 나중에 회사 웹사이트에서 녹화된 내용이 제공될 것입니다.

Co-Diagnostics, Inc. (NASDAQ: CODX), une société de diagnostic moléculaire, a annoncé la date de publication de ses résultats financiers du deuxième trimestre 2024. La société dévoilera ses bénéfices le jeudi 8 août 2024, après la clôture du marché. Après la publication, Co-Diagnostics organisera une conférence téléphonique et un webinaire à 16h30 ET pour discuter des résultats avec des analystes et des investisseurs institutionnels.

La conférence téléphonique mettra en avant des figures clés de la direction, notamment le PDG Dwight Egan, le directeur financier Brian Brown et le responsable des relations investisseurs Andrew Benson. Les personnes intéressées peuvent accéder au webinaire via le site web des relations avec les investisseurs de la société ou rejoindre la conférence téléphonique en utilisant les numéros de téléphone nationaux et internationaux fournis. Pour ceux qui ne peuvent pas assister en direct, un enregistrement sera disponible plus tard sur le site web de la société.

Co-Diagnostics, Inc. (NASDAQ: CODX), ein Unternehmen für molekulare Diagnostik, hat das Veröffentlichungsdatum seiner Finanzergebnisse für das zweite Quartal 2024 bekannt gegeben. Das Unternehmen wird seine Einnahmen am Donnerstag, den 8. August 2024, nach Börsenschluss veröffentlichen. Nach der Bekanntgabe wird Co-Diagnostics um 16:30 Uhr ET eine Telefonkonferenz und Webcast veranstalten, um die Ergebnisse mit Analysten und institutionellen Investoren zu besprechen.

In der Konferenz werden wichtige Führungspersönlichkeiten teilnehmen, darunter CEO Dwight Egan, CFO Brian Brown und der Leiter der Investor Relations, Andrew Benson. Interessierte können über die Investor-Relations-Website des Unternehmens auf den Webcast zugreifen oder unter Verwendung der bereitgestellten nationalen und internationalen Telefonnummern an der Telefonkonferenz teilnehmen. Für diejenigen, die nicht live teilnehmen können, wird eine Aufzeichnung später auf der Website des Unternehmens zur Verfügung gestellt.

Positive
  • None.
Negative
  • None.

SALT LAKE CITY, July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2024 results on Thursday, August 8, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts and institutional investors. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

The conference call and webcast will be available via:

Webcast: ir.codiagnostics.com on the Events & Webcasts page

Conference Call: 844-481-2661 (domestic) or 412-317-0652 (international)

If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.

About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-second-quarter-2024-earnings-release-date-and-webcast-302206409.html

SOURCE Co-Diagnostics

FAQ

When will Co-Diagnostics (CODX) release its Q2 2024 earnings?

Co-Diagnostics (CODX) will release its second quarter 2024 earnings on Thursday, August 8, 2024, after the market close.

How can I access Co-Diagnostics' (CODX) Q2 2024 earnings call?

You can access Co-Diagnostics' Q2 2024 earnings call via webcast at ir.codiagnostics.com or by phone at 844-481-2661 (domestic) or 412-317-0652 (international) on August 8, 2024, at 4:30 p.m. ET.

Who will be participating in Co-Diagnostics' (CODX) Q2 2024 earnings call?

The earnings call will feature CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson from Co-Diagnostics (CODX).

What if I miss Co-Diagnostics' (CODX) live Q2 2024 earnings webcast?

If you miss the live webcast, a recording of Co-Diagnostics' (CODX) Q2 2024 earnings call will be made available on the company's website later.

Co-Diagnostics, Inc.

NASDAQ:CODX

CODX Rankings

CODX Latest News

CODX Stock Data

41.80M
31.91M
5.4%
15.31%
0.97%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SALT LAKE CITY